SCP
TEVA icon

Seizert Capital Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Seizert Capital Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-460,261
Closed -$16.7M – 241
2016
Q4 		$16.7M Buy
460,261
+68,561
+18% +$2.74M 0.59% 53
2016
Q3 		$18M Buy
391,700
+181,606
+86% +$9.48M 0.67% 52
2016
Q2 		$10.6M Buy
210,094
+60,224
+40% +$3.21M 0.4% 65
2016
Q1 		$8.02M Buy
149,870
+42,384
+39% +$2.49M 0.27% 75
2015
Q4 		$7.05M Sell
107,486
-8,051
-7% -$498K 0.22% 81
2015
Q3 		$6.52M Sell
115,537
-51,391
-31% -$3.33M 0.2% 85
2015
Q2 		$9.87M Buy
166,928
+5,141
+3% +$317K 0.25% 79
2015
Q1 		$10.1M Sell
161,787
-2,781
-2% -$162K 0.25% 81
2014
Q4 		$9.46M Buy
164,568
+182
+0.1% +$10.1K 0.2% 81
2014
Q3 		$8.84M Sell
164,386
-5,149
-3% -$273K 0.18% 83
2014
Q2 		$8.89M Buy
169,535
+72,807
+75% +$3.72M 0.18% 81
2014
Q1 		$5.11M Buy
+96,728
New +$4.47M 0.12% 79
2013
Q3 		– Sell
-7,960
Closed -$312K – 214
2013
Q2 		$312K Buy
+7,960
New +$310K 0.01% 167

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Seizert Capital Partners's TEVA Position: Q1 2017 in Review

Seizert Capital Partners sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 460,261 shares — an estimated $16.7M sold.

Seizert Capital Partners first reported a position in TEVA in Q2 2013 and held it in 13 quarters. The position peaked at $18M in Q3 2016. 688 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

  • Seizert Capital Partners reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Seizert Capital Partners sold 460,261 Teva Pharmaceuticals shares in Q1 2017, an estimated $16.7M.
  • Seizert Capital Partners first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 13 quarters.
  • Seizert Capital Partners's Teva Pharmaceuticals position peaked at $18M in Q3 2016.
  • 688 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on Seizert Capital Partners's 13F filing for Q1 2017, filed 10 May 2017.